Related Experiment Video
Updated: Jul 12, 2025
Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
Published on: November 21, 2023
Targeting the COMMD4-H2B protein complex in lung cancer
Ming Tang1,2, Joshua T Burgess1,3, Mark Fisher1
1Queensland University of Technology (QUT), School of Biomedical Sciences, Centre for Genomics and Personalised Health at the Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Background:
Lung cancer is the biggest cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 85-90% of all lung cancers. Identification of novel therapeutic targets are required as drug resistance impairs chemotherapy effectiveness. COMMD4 is a potential NSCLC therapeutic target. The aims of this study were to investigate the COMMD4-H2B binding pose and develop a short H2B peptide that disrupts the COMMD4-H2B interaction and mimics COMMD4 siRNA depletion.
Methods:
Molecular modelling, in vitro binding and site-directed mutagenesis were used to identify the COMMD4-H2B binding pose and develop a H2B peptide to inhibit the COMMD4-H2B interaction. Cell viability, DNA repair and mitotic catastrophe assays were performed to determine whether this peptide can specially kill NSCLC cells.
Results:
Based on the COMMD4-H2B binding pose, we have identified a H2B peptide that inhibits COMMD4-H2B by directly binding to COMMD4 on its H2B binding binding site, both in vitro and in vivo. Treatment of NSCLC cell lines with this peptide resulted in increased sensitivity to ionising radiation, increased DNA double-strand breaks and induction of mitotic catastrophe in NSCLC cell lines.
Conclusions:
Our data shows that COMMD4-H2B represents a novel potential NSCLC therapeutic target.
Insights
Researchers identified a novel therapeutic target for non-small cell lung cancer (NSCLC) by developing a peptide that disrupts the COMMD4-H2B interaction, enhancing cancer cell sensitivity to radiation.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Lung cancer is a leading cause of cancer mortality globally, with non-small cell lung cancer (NSCLC) being the most prevalent subtype.
- Drug resistance limits chemotherapy effectiveness, necessitating the identification of novel therapeutic targets for NSCLC.
- COMMD4 has emerged as a potential therapeutic target in NSCLC.
Purpose of the Study:
- To elucidate the binding interaction between COMMD4 and H2B.
- To design a short H2B peptide capable of disrupting the COMMD4-H2B interaction.
- To investigate if the developed peptide can mimic the effects of COMMD4 siRNA depletion in NSCLC.
Main Methods:
- Utilized molecular modeling to predict the COMMD4-H2B binding pose.
- Employed in vitro binding assays and site-directed mutagenesis to validate the binding and develop the peptide.
- Assessed peptide efficacy through cell viability, DNA repair, and mitotic catastrophe assays in NSCLC cell lines.
Main Results:
- Successfully identified the COMMD4-H2B binding pose and developed an H2B peptide that inhibits this interaction both in vitro and in vivo.
- Demonstrated that the peptide binds directly to COMMD4 at the H2B binding site.
- Observed that NSCLC cells treated with the peptide exhibited increased sensitivity to ionizing radiation, elevated DNA double-strand breaks, and induced mitotic catastrophe.
Conclusions:
- The COMMD4-H2B interaction represents a promising novel therapeutic target for non-small cell lung cancer.
- The developed H2B peptide shows potential as a therapeutic agent for NSCLC, particularly in combination with radiation therapy.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...